Online inquiry

IVTScrip™ mRNA-Human ACD, (Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK10920MR)

This product GTTS-WK10920MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the ACD protein. This product can be used in Natural killer T (NKT) cell-related researches.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001082486.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 65057
UniProt ID Q96AP0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ACD, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK10920MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK13430MR IVTScrip™ mRNA-Human Additional GABA Compounds, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Additional GABA Compounds
GTTS-WK12489MR IVTScrip™ mRNA-Human ADAM12, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADAM12
GTTS-WK28697MR IVTScrip™ mRNA-Human ASB16-AS1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASB16-AS1
GTTS-WK15233MR IVTScrip™ mRNA-Human ANKRD62, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANKRD62
GTTS-WK21443MR IVTScrip™ mRNA-Human ALS2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALS2
GTTS-WK13174MR IVTScrip™ mRNA-Human ADTRP, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADTRP
GTTS-WK11339MR IVTScrip™ mRNA-Human ADGRE5, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADGRE5
GTTS-WK24967MR IVTScrip™ mRNA-Human ARF5, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARF5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW